These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29864243)

  • 1. Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats.
    Licari G; Milne RW; Somogyi AA; Sallustio BC
    Pharmacol Res Perspect; 2018 Jun; 6(3):e00406. PubMed ID: 29864243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats.
    Licari G; Somogyi AA; Milne RW; Sallustio BC
    Xenobiotica; 2015 Jan; 45(1):3-9. PubMed ID: 25050791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
    Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
    Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.
    Chong CR; Drury NE; Licari G; Frenneaux MP; Horowitz JD; Pagano D; Sallustio BC
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1485-91. PubMed ID: 26376650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
    Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
    Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of perhexiline maleate on lipid metabolism in the rat. III. Liver gangliosides after administration of high doses of perhexiline maleate.
    Hoenig V; Werner F
    Pharmacol Res Commun; 1980 Jan; 12(1):29-33. PubMed ID: 7384161
    [No Abstract]   [Full Text] [Related]  

  • 7. Perhexiline.
    Ashrafian H; Horowitz JD; Frenneaux MP
    Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perhexiline maleate-induced cirrhosis.
    Pessayre D; Bichara M; Degott C; Potet F; Benhamou JP; Feldmann G
    Gastroenterology; 1979 Jan; 76(1):170-7. PubMed ID: 213349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective pharmacokinetics of perhexiline.
    Gould BJ; Amoah AG; Parke DV
    Xenobiotica; 1986 May; 16(5):491-502. PubMed ID: 3739369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.
    Kennedy JA; Unger SA; Horowitz JD
    Biochem Pharmacol; 1996 Jul; 52(2):273-80. PubMed ID: 8694852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of perhexiline maleate (Pexid) and alcohol on rat liver.
    McDonald GS
    Br J Exp Pathol; 1979 Jun; 60(3):294-9. PubMed ID: 475976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of sulfobromophthalein biliary excretion and inhibition of glutathione S-transferase activity induced by perhexiline maleate in rats.
    Mariscal MA; Muñoz ME; Collado PS; Esteller A; Gonzalez J
    Biochem Pharmacol; 1988 Sep; 37(18):3461-5. PubMed ID: 3421996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [(18)F]GE-180.
    Chau WF; Black AM; Clarke A; Durrant C; Gausemel I; Khan I; Mantzilas D; Oulie I; Rogstad A; Trigg W; Jones PA
    Nucl Med Biol; 2015 Sep; 42(9):711-9. PubMed ID: 26072270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions.
    Deschamps D; DeBeco V; Fisch C; Fromenty B; Guillouzo A; Pessayre D
    Hepatology; 1994 Apr; 19(4):948-61. PubMed ID: 8138270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrastructural alterations in peripheral nerve trunks of rats subchronically treated with chlorphentermine or perhexiline.
    Albert C; Lüllmann-Rauch R
    Arzneimittelforschung; 1983; 33(1):125-7. PubMed ID: 6681963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart.
    Kennedy JA; Kiosoglous AJ; Murphy GA; Pelle MA; Horowitz JD
    J Cardiovasc Pharmacol; 2000 Dec; 36(6):794-801. PubMed ID: 11117381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
    Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
    Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of perhexiline maleate on lipid metabolism in the rat.
    Hoenig V; Werner F
    Arzneimittelforschung; 1979; 29(9):1395-8. PubMed ID: 583247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.
    Drury NE; Licari G; Chong CR; Howell NJ; Frenneaux MP; Horowitz JD; Pagano D; Sallustio BC
    Br J Clin Pharmacol; 2014 May; 77(5):789-95. PubMed ID: 24117487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic mechanisms of action of perhexiline in heart failure.
    George CH; Mitchell AN; Preece R; Bannister ML; Yousef Z
    Expert Opin Ther Pat; 2016 Sep; 26(9):1049-59. PubMed ID: 27455171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.